Merck’s New Pill Matches Shots in Lowering Bad Cholesterol
New research showcased at a recent conference in New Orleans reveals that an innovative pill has significantly reduced bad cholesterol levels in patients at risk of heart-related issues. This breakthrough marks a pivotal moment for Merck, as they aim to enhance heart health through oral medication.
New Cholesterol-Lowering Medication: Enlicitide
Merck’s latest development, Enlicitide, acts as a potent oral PCSK9 inhibitor. This once-daily pill was evaluated in a Phase 3 clinical trial involving 2,900 participants with elevated LDL cholesterol levels, known as “bad” cholesterol.
Trial Insights and Results
The study specifically targeted individuals who had previously suffered major cardiovascular events or were at significant risk due to factors like obesity or diabetes. Noteworthy findings include:
- LDL cholesterol reduction of up to 60% in trial subjects.
- Approximately two-thirds of the patients achieved at least a 50% reduction in their cholesterol levels.
Impact on Cardiovascular Health
This oral medication presents a strategic alternative for patients unable to manage their cholesterol with statins alone. The trial aimed to match the effectiveness of injected monoclonal antibodies, which are known for their strong impact on cholesterol reduction.
Target Population
The participants included individuals with serious cardiovascular conditions, such as:
- Coronary heart disease
- History of heart attacks
- Stroke
- Peripheral artery disease
The findings from this trial are expected to influence treatment protocols for managing high cholesterol, especially among those prone to cardiovascular events.
